The OECD program to validate the rat uterotrophic bioassay. Phase 2: dietary phytoestrogen analyses. by Owens, William et al.
The Organisation for Economic Cooperation
and Development (OECD) initiated a high-
priority activity in 1997 to develop new and
revised guidelines for screening and testing
potential endocrine disrupters (OECD
1998a). One activity is to validate the utero-
trophic bioassay to screen suspected estrogen
receptor (ER) agonists or antagonists to iden-
tify those with in vivo activity and to evaluate
positive compounds for deﬁnitive testing. The
validation program demonstrates that the
uterotrophic bioassay is reproducible and
reliable for a potent reference estrogen,
17α-ethinyl estradiol (EE); ﬁve weak ER ago-
nists, bisphenol A (BPA), genistein (GN),
methoxychlor, nonylphenol (NP), and 1,1,1-
trichloro-2,2-bis(o,p´-chlorophenyl)methane
or o,p´-DDT; and a negative chemical, dibutyl-
phthalate (Kanno et al. 2001, 2003a, 2003b).
Among several protocol parameters,
phytoestrogens in the laboratory diet are a
possible source of interference with the
uterotrophic bioassay. There are rare reports
that laboratory diets induced statistically sig-
niﬁcance increases in uterine weights or inter-
fered with the bioassay (Drane et al. 1975,
1980; Huggins et al. 1954; Zarrow et al.
1953). Analyses show that many laboratory
diets contain GN, daidzein (DN), and other
phytoestrogens at levels of 100 µg/g diet
(Boettger-Tong et al. 1998; Brown and
Setchell 2001; Degen et al. 2002; Thigpen et
al. 1999a, 1999b). Isolated phytoestrogens,
such as GN, DN, and coumestrol (CM),
have biological activity consistent with an
estrogen mode of action (Whitten et al. 1992;
Whitten and Naftolin 1992; Whitten and
Patisaul 2001). Phytoestrogens are weak ago-
nists for the ER (Branham et al. 2002) and
elicit statistically signiﬁcant increases in uter-
ine weights at high doses in the uterotrophic
bioassay (Bickoff et al. 1962; Farmakalidis et
al. 1985; Farmakalidis and Murphy 1984;
Jefferson and Newbold 2000; Kanno et al.
2003a, 2003b; Markaverich et al. 1995;
Odum et al. 1997; Perel and Linder 1970).
The best-characterized phytoestrogen, GN,
induces uterine weight increases, accelerates
vaginal opening, and elicits other responses
associated with estrogenic activity at doses of
300 µg/g diet or 30 mg/kg/day (Casanova
et al. 1999; Fritz et al. 1998; Santell et al.
1997; You et al. 2002a, 2002b).
Three issues are addressed in this article:
a) whether changes in uterine weights are
associated with phytoestrogen levels in labora-
tory diets, suggesting a possible interference
with uterotrophic bioassay; b) what levels of
phytoestrogens may lead to interference and
should be avoided; and c) what other other
instances of apparent interference are present
and what are their causes. This article
addresses these questions by comparing the
results of uterotrophic bioassays from the
OECD phase 2 validation studies using both
the intact, immature as well as the adult
ovariectomized (OVX) versions of the
uterotrophic bioassay (Kanno et al. 2003a,
2003b). Laboratory diets were submitted for
phytoestrogen analyses, and the response of
the bioassay with two particularly weak
agonists, BPA and NP, was examined.
Materials and Methods
Materials. Diets from 20 laboratories partici-
pating in the OECD phase 2 validation
studies of the uterotrophic assay were sent to
the Syngenta CTL Laboratory (Macclesﬁeld,
Cheshire, UK). Each laboratory was requested
to send all lots used and to record diet name,
source, and lot number as well as the groups
fed each lot (Table 1). At CTL, the diet sam-
ples were coded to blind the analytical labora-
tory, packaged and sent to Bioclinical Services
International (Cardiff, UK) for phytoestrogen
analyses of GN, DN, and CM. Laboratory
codes, dietary codes, diet identities, and other
details are shown in Table 1.
Dietary analyses. The diets were analyzed
using the method described previously in
Odum et al. (2001). Sample preparation was
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Many commercial laboratory diets have detectable levels of isoﬂavones (e.g., phytoestrogens such as
genistein [GN]) that have weak estrogenic activity both in vitro and in vivo. During validation
studies of the uterotrophic bioassay, diet samples from 20 participating laboratories were collected
and analyzed for three major phytoestrogens: GN, daidzein (DN), and coumestrol (CM). Soy
phytoestrogens GN and DN were found at total phytoestrogen levels from 100 to 540 µg/g labora-
tory diet; a forage phytoestrogen, CM, ranged from nondetectable to 4 µg/g laboratory diet. The
phytoestrogen levels were compared with both baseline uterine weights of the control groups and
with the relative uterine weight increase of groups administered two weak estrogen agonists:
bisphenol A (BPA) and nonylphenol (NP). The comparison uses a working assumption of additiv-
ity among the phytoestrogens, despite several signiﬁcant qualiﬁcations to this assumption, to esti-
mate total genistein equivalents (TGE). Some evidence was found that phytoestrogen levels in the
diet > 325–350 µg/g TGE could diminish the responsiveness of the uterotrophic bioassay to weak
agonists. This was especially true for the case of the intact, immature female version of the
uterotrophic bioassay, where higher food consumption relative to body weight leads to higher
intakes of dietary phytoestrogens versus ovariectomized adults. This dietary level is sufﬁcient in the
immature female to approach a biological lowest observable effect level for GN of 40–50
mg/kg/day. These same data, however, show that low to moderate levels of dietary phytoestrogens
do not substantially affect the responsiveness of the assay with weak estrogen receptor agonists such
as NP and BPA. Therefore, laboratories conducting the uterotrophic bioassay for either research or
regulatory purposes may routinely use diets containing levels of phytoestrogens < 325–350 µg/g
TGE without impairing the responsiveness of the bioassay. Key words: coumestrol, daidzein, diet,
endocrine disruption, estrogen, genistein, phytoestrogen, rat uterus, uterotrophic. Environ Health
Perspect 111:1559–1567 (2003). doi:10.1289/ehp.5949 available via http://dx.doi.org/ [Online
23 January 2003]
Rat Uterotrophic Bioassay | Mini-Monographbased on Setchell et al. (1987) and has been
used for both food and biological samples
(Morton et al. 1994; Thigpen et al. 1999b).
The coefﬁcient of variation for intraassay preci-
sion was 3–13% (Morton et al. 1994) and was
determined prior to the present study by mul-
tiple analysis of the same diet batch on separate
occasions where results were within 10%.
Aliquots of the diets (e.g., 10 pellets) were
ground to a homogenous powder. A 100-mg
aliquot of each powder was then extracted with
80% methanol (80 mL) by ultrasonication
(3 min), followed by incubation at 60°C for
2 hr and further ultrasonication (3 min). The
mixtures were cooled and made up to 100 mL
with methanol; 0.1-mL samples were taken
and mixed with 0.05 mL methanol containing
internal standards, namely, deuterated d4-DN,
d4-GN, d4-CM, and dihydroxyﬂavone. The
samples were then treated with β-glucosidase
to hydrolyze the glycosides, for example,
genistin and diadzin, with incubation
overnight at 37°C in sodium acetate buffer
(0.1 M, pH 5.0, ﬁnal volume 2.5 mL). After
hydrolysis, products were extracted twice with
ethyl acetate (2 × 4 mL), and extracts were
combined and evaporated to dryness. The
residues were reconstituted in chloroform:
heptane:methanol (10:10:1). The reconstituted
samples were applied to short Sephadex LH20
columns, washed with chloroform:heptane:
methanol (10:10:1, 4 mL), and eluted with
methanol. After evaporation of the methanol,
samples were derivatized for gas chromato-
graphy–mass spectrometry (GC-MS) with
n-(t-butyldimethylsilyl)-N-methyltrifluoro-
acetamide containing 1% t-butyldimethylsilyl
chloride (0.04 mL) in acetonitrile (0.04 mL) at
65°C for 2 hr. After solvent evaporation,
derivatized residues were reconstituted in ethyl
acetate (0.02 mL) for GC-MS.
GC-MS was carried out on a DB5 MS
bonded silica capillary column (10 m ×
0.25 mm, phase thickness 0.25 µm) using
helium as carrier gas and a temperature of
70–300°C at 40°C/min. Isotope dilution MS
was performed using selective ion monitoring at
mass 425 for DN, 429 for d4-DN, 555 for
GN, 559 for d4-GN, 496 for CM, and 500 for
d4-CM. Peak area ratios were determined for
analytes and internal standards. Calibration
curves were constructed, and sample concentra-
tions of GN, DN, and CM were determined.
Uterotrophic bioassay and statistics.
All conditions and procedures for the
uterotrophic bioassay and statistical methods
have been reported previously (Kanno et al.
2001, 2003a, 2003b). Studies were per-
formed in accordance with OECD’s animal
care guidelines (OECD 2000) and appropri-
ate national regulations. The BPA and NP
results are expressed as the ratio of the geo-
metric means of uterine weights (relative to
vehicle control) after adjusting for body
weight (bw) of the animal at necropsy, along
with lower and upper 95% conﬁdence levels
for those means.
Results
Analytical results. The analytical results for
GN, DN, and CM are shown in Table 2.
The results indicate a substantial presence of
soy products with all diets containing
detectable GN and DN, with DN consis-
tently lower than GN. Samples 17 and 22
had the lowest total GN and DN levels of
approximately 100 µg phytoestrogens/g diet,
sample 26 had the highest levels with 541 µg
phytoestrogens/g diet, and most samples had
levels between 150 and 350 µg phytoestro-
gens/g diet. In contrast, CM, found in forage
crops such as alfalfa, was not detected in 8 of
26 samples and did not exceed 4.1 µg/g diet
in any sample.
In three cases, the same lot number of diet
was submitted by more than one laboratory.
These three possible duplicates were diet codes
4 and 8, diet codes 5 and 9, and diet codes 12
and 13 (Tables 1 and 2). Although not precise
split samples, it was interesting to compare the
analytical results for these samples. Analyses of
samples 4 and 8 closely correspond for all
three substances. For samples 5 and 9, the cor-
respondence is excellent for DN, but there is
an approximately 20% difference in GN levels
at 216 and 170 µg/g diet, respectively. For
samples 12 and 13, the DN and CM corre-
spondences are excellent, but the GN analyses
differ with 218 and 180 µg/g diet, respec-
tively. Where different lots of the same diet
were submitted, the pattern of analytical
results was consistent within a diet.
Food consumption. Eight participating
laboratories recorded food consumption for
intact, immature females, and three recorded
data for OVX females. Intact, immature female
displayed a rapid rise in food consumption
from approximately 2–4 g/animal on day 1 to
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Table 1. Laboratory and diet code numbers, diet identity, and details for phase 2 uterotrophic validation
program.
Lab Diet
code code Diet identiﬁcation, details, and commentsa
1 CRF-1 diet from Oriental Yeast Co., Ltd. Three different lots of the same diet were submitted, each 
lot was analyzed. Records show that lot #000208 was also used during the 
study, but a sample of this lot was not submitted.
4 Lot # 000405
5 Lot # 000509
6 Lot # 000705
2 CRF-1 from Oriental Yeast Co., Ltd. Three different lots of the same diet were submitted; each lot 
was analyzed.
8 Lot # 000405
9 Lot # 000509
10 Lot # 000602
32 0 MF pelleted diet from Oriental Yeast Co., Ltd., lot # 000412A1
42 Kliba from Provimi Kliba, lot # 20/00. Three samples with the same lot number were submitted. 
Only one lot was analyzed.
53 Certiﬁed rodent diet 5002 from PMI, lot 29 Sept 99.b
61 1 AO4C 10 pelleted maintenance diet from UAR, lot # 00331. Two samples with same lot number 
were submitted. Only one lot was analyzed.
71 2 CE2 diet from CLEA Japan Inc., lot # E2050-P8
82 4 RM3 from Special Diet Services Ltd., lot # 15980. This diet is used with dams only.
25 RM1 from Special Diet Services Ltd., lot # 6458. This diet is used with OVX and also immatures 
after weaning (during bioassay).
9 MF pelleted diet from Oriental Yeast Co., Ltd. Two different lots of the same diet were submitted; 
each lot was analyzed.
14 Lot # 512
15 Lot # 612
11 13 CE2 diet from CLEA Japan Inc., lot # E2050-P8
12 7 Certiﬁed rodent diet 5002 from PMI, Lot # June 26 00 3D
13 1 Altromin 1324; from Altromin, Lot # not provided
14 17 AOC4 10 certiﬁed rodent meal from UAR, lot # 90928. Three samples were provided with same lot 
number; two were combined because of small sample
size, and the combined sample was analyzed.
15 19 RM3 from Special Diet Services Ltd., Lot # 6657
16 16 Altromin 1324 from Altromin; Lot number not provided
17 21 Altromin 1324 from Altromin; Lot number not provided
18 23 Certiﬁed rodent diet 5014 from PMI. Lot number not provided
19 22 RM1 from Special Diet Services Ltd., lot # 6706. Two samples with same lot number were 
submitted. Only one lot was analyzed
20 26 Altromin MT from Altromin, lot # 0.003 MT
21 18 GLP4RF25 from Mucedola, lot # 37129-A3
aDetailed information on diets can be obtained from the author of this article. bIn the case of laboratory 5 and diet sample 3,
it was discovered that the diet sample had not been used in the uterotrophic studies, but had been used in parallel studies
to validate the castrated male or Hershberger bioassay and was submitted in error. Although the phytoestrogen analyses
are reported in Table 2, these data have not been used in Figures 3–6.6–11 g/animal on day 4 before necropsy. As
intact, immature animals were group housed
with no less than three animals per cage, the
value is based on mean food consumption per
animal for a cage. For the OVX females, food
consumption was more stable at 14–24
g/animal on day 4 among the laboratories. All
amounts may include wastage and spillage.
Where animals had diminished increases in
body weight or even body weight losses, food
consumption was lower, and these cases were
not considered representative. The approxi-
mate food intake ranges used below were then
130–170 g/kg bw/day for immature animals
and 60–75 g/kg bw/day for OVX animals.
Vehicle control uterine weights. The
blotted vehicle control uterine weights from
the dose–response and coded single-dose stud-
ies have been previously reported (Kanno et al.
2003a, 2003b). However, additional un-
reported controls for EE doses were conducted
in some laboratories during the dose–response
studies, and these are included herein.
The arithmetic mean blotted weights for
the intact, immature groups ranged from a
minimum of 14.8 mg to a maximum of 58.0
mg in 60 groups. As shown in Figure 1A,
when these data are plotted in rank numerical
ascending order, an extended tail of high
vehicle control uterine weights appears in ﬁve
groups from laboratories 6, 20, and 21. These
high uterine weight values are double the
vehicle control uterine values recorded at the
lower end of the range and are a possible con-
cern for reducing the dynamic range and
responsiveness of the uterotrophic bioassay. A
similar tail was not clearly evident in the adult
OVX vehicle control groups (Figure 2), where
the arithmetic mean blotted weights ranged
from 71.5 mg to 110.7 mg in 34 groups. The
highest OVX control uterine weight value
was again recorded in laboratory 6.
One other observation was notable for
the adult OVX animals. In phase 1, the rec-
ommended time of regression between
ovariectomy and the ﬁrst substance adminis-
tration was 10 days. This was changed to
≥ 14 days in phase 2; the added time appears
to allow a further decrease in the mean blot-
ted vehicle control weights (Figure 2) and
should slightly improve the responsiveness of
the OVX version.
Body weights and uterine weights.
Differences in body weight are one factor that
could lead to differences in blotted uterine
weights. Therefore, the mean uterine weights
of control groups were plotted against their
respective body weights.
There is a modest increase in uterine
weight with increasing body weight in the
intact, immature animals (Figure 3). Five
laboratories have been highlighted in Figure 3
and include laboratories 6, 20, and 21 noted
above. First, high body weights do not
account for higher blotted uterine weight
values in these laboratories. Second, the lowest
blotted uterine weights were in laboratory 14.
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Figure 1. Group mean absolute blotted uterine con-
trol weights (mg) for all intact, immature female
groups in phase 2 dose–response and coded sin-
gle-dose studies where dietary analyses were per-
formed. The weights are arranged in ascending
rank order to illustrate the distribution.
Figure 2. Group mean absolute blotted uterine con-
trol weights (milligrams) for all adult OVX groups in
phase 2 dose–response and coded single-dose
studies where dietary analyses were performed
(dark blue diamonds), and for all adult OVX groups
in phase 1 where no dietary analyses were per-
formed (light blue squares). The weights are
arranged in ascending rank order to illustrate the
distribution. Animals in phase 1 underwent a 10-
day period of regression after ovariectomy before
test substances were administered, and animals in
phase 2 underwent a 14-day period of regression.
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Figure 3. Group mean absolute blotted uterine con-
trol weights (milligrams) plotted against the
respective man absolute body weights for intact,
immature female groups in phase 2. The results of
speciﬁc groups from laboratories 6, 14, 19, 20, and
21 that are discussed in the text have been high-
lighted in light blue and labeled. 
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Table 2. Phytoestrogen analyses for laboratory diets in phase 2 of uterotrophic bioassay validation
program and estimated TGE for the diet.
Lab Diet DN GN CM Estimated TGEa
code code (µg/g diet) (µg/g diet) (µg/g diet) (µg/g diet)
1491.2 206.5 3.1 310
5 101 216 ND 297
6 83.7 198.6 ND 266
2884.1 190 ND 257
98 5 169.8 2.3 261
10 40.7 123.3 1.8 174
32 0130.9 221.8 0.8 335
4270.9 151.5 ND 208
5b 3 88.1 204.2 2.5 300
61 1 53.9 132.6 ND 176
71 2101.7 238.3 1.8 338
82 4 48.7 156.8 ND 196
25 53.2 135.3 ND 178
91 4 85.8 200.1 3.8 307
15 84.7 175.1 1.3 256
11 13 113.2 180.2 2.8 299
12 7 117 218.3 ND 312
13 1 113.8 239.6 1.3 344
14 17 28.4 72.9 2.6 122
15 19 48 131.9 1.5 185
16 16 84 144.7 2.3 235
17 21 90.1 177.1 2.3 272
18 23 77.8 164.8 0.8 235
19 22 29.2 72.4 0.3 99
20 26 186.6 354.7 0.9 513
21 18 121.2 226.2 4.1 364
ND, not determined. 
aThe equivalency factor used to convert DN to GN was 0.8, and the equivalency factor used to convert CM to GN was 10.
The converted microgram per gram diet were then summed to give TGE. bIn the case of laboratory 5 and diet sample 3, it
was discovered that the diet sample had not been used in the uterotrophic studies, but had been used in parallel studies
to validate the castrated male or Hershberger bioassay and was submitted in error. Although the phytoestrogen analyses
are reported in Table 2, these data have not been used in Figures 3–6.Third, laboratory 19 was noted to be less
responsive in both dose–response and coded
single-dose studies (Kanno et al. 2003a,
2003b), but appears to be unremarkable. In
the OVX studies, uterine weights were rela-
tively uniform, and no association with body
weight is discernable (data not shown).
Calculation of genistein equivalents. To
assess any interaction between dietary phyto-
estrogens and uterine weights on responsive-
ness, a working assumption was that different
phytoestrogens interact in a simple, additive
manner. This permits a proxy calculation of
total genistein equivalents (TGE) in the diet.
The assumption of additivity has signifi-
cant qualiﬁcations. First, there are two forms of
the ER, α and β, with different tissue distribu-
tions (Kuiper et al. 1996, 1997) and with some
differences in binding afﬁnity, particularly for
phytoestrogens (Kuiper et al. 1997, 1998).
Second, the ability of the ER to mediate gene
transcription depends upon interaction with a
set of co-activators at the external surface of the
ligand-binding domain (McKenna et al. 1999;
Moras and Gronemeyer 1998; Xu et al. 1999).
These coactivators are tissue dependent, sup-
porting the concept of selective estrogen mod-
ulators to explain the differential and even
opposite response of certain ligands in one tis-
sue and not another (Safe et al. 2001; Shang
and Brown 2002). A classic example is tamox-
ifen, an estrogen antagonist in breast tissue, but
partial agonist in uterine tissue. Therefore, data
from the same tissue and end point should be
used to construct any estimated estrogen equiv-
alents, for example, an increase the uterine
weight, and extrapolations to other tissues and
end points done with care.
The second qualiﬁcation arises from data
generated from the co-administration of sev-
eral estrogenic compounds in the uterotrophic
bioassay (Edgren and Calhoun 1957, 1960,
1961). These results question direct additivity
and linearity of the equivalency assumption
across a range of doses, suggesting some degree
of additivity in the lower region of the
dose–response curve and antagonistic activity
in the higher region of the dose–response
curve. Because the concern here is in the lower
region of the dose–response curve and all data
used are deliberately drawn from that region,
additivity will be presumed.
The third qualiﬁcation rests on the need to
have relevant, high-quality and comparable in
vivo uterine data for each chemical. However,
the available uterotrophic data for GN, DN,
and CM are fragmented between rat and
mouse, are often from vaguely described pro-
tocols, have different selected doses and spac-
ing of those doses and different routes of
administration, and use wet uterine weights
with imbibed ﬂuid in some studies and blotted
uterine weight in others (Bickoff et al. 1962;
Farmakalidis and Murphy 1984; Farmakalidis
et al. 1985; Jefferson and Newbold 2000;
Markaverich et al. 1995; Odum et al. 1997;
Perel and Linder 1970). A review of these data
supports the qualitative conclusions that a)
GN is slightly more potent orally than DN;
and b) CM is signiﬁcantly more potent orally
than either GN or DN, probably by an order
of magnitude or more. Stressing the high
degree of uncertainty, the values chosen for
equivalency factors are 0.8 to convert DN into
GN units on a weight basis, and 10 to convert
CM into GN units on a weight basis.
Calculation of total phytoestrogen intake.
To calculate approximate TGE intake per
kilogram body weight per day, conversion
factors are needed for both immature and
OVX animals. For the immature animals, an
average 55 g body weight and average intake
of 8.2 g/day of laboratory diet yields a factor
of 150 g/kg bw/day to convert the dietary
level of TGE into a daily intake. For the
OVX animals, an average 260 g body weight
and average intake of 18.5 g/day laboratory
diet yields a conversion factor of 67.5 g/kg
bw/day. An essential point evident from these
conversion factors is that phytoestrogen
intakes on a body weight basis will be slightly
greater than 2-fold that of OVX animals on
the same lot of laboratory diet.
Comparison of control uterine weights to
total genistein equivalents. The plausible
effect of concern is that phytoestrogen intake
would increase control uterine weights,
thereby diminishing the dynamic range of the
bioassay and affecting the ability to detect
very weak agonists. To ﬁrst examine this pos-
sibility, vehicle control uterine weights have
been pooled into two sets, intact, immature
and adult OVX, to plot uterine weight values
against respective TGE intakes.
The intact, immature data intakes ranged
from 18 to 75 mg TGE/kg bw/day (Figure 4A)
and suggest that dietary phytoestrogens lead to
a slow progressive increase in uterine control
weights. This suggestion is supported by labora-
tories 20 and 21, where both have high uterine
control values and the highest TGE intakes.
This suggestion is also supported by laboratory
14 with the second lowest dietary TGE value
and the lowest control uterine weights, but
these were also the animals with the lowest
body weights. A linear least-squares analysis of
these data yields the equation y = 0.407x +
14.08 and an r2 value of 0.319. Omission of
laboratories 20 and 21 with the highest phytoe-
strogen diets reduces the equation to y = 0.223x
+ 20.31 with an r2 value of 0.109. This still
includes two possible inconsistencies: a) labora-
tory 6 has the highest control uterine weight
value and an intermediate TGE value, and
b) laboratory 19 with the lowest dietary TGE
value has almost twice the control uterine
weights as those in laboratory 14.
The data for the adult OVX blotted vehicle
control uterine weights ranged from 12 to
23 mg TGE/kg bw/day and are shown in
Figure 4B. In this case, the diet appears to have
no impact on the control uterine weights, and
the OVX intakes were half that of the intact,
immature animals on the same or similar diets.
Comparison of weak agonist responses to
total genistein equivalents. A second method
of evaluating the possible effect of phyto-
estrogens would be to examine the responsive-
ness of the uterus to weak estrogen agonists at
various dietary intake levels. The largest com-
parable data sets for weak estrogen agonists are
those from the administration of BPA and NP
by oral gavage and sc injection in the OECD
validation studies. Three subsets of data have
again been analyzed for each substance: intact,
immature females by po and sc administra-
tion, and OVX adults by sc administration
(protocols A, B, and C, respectively) (Kanno
et al. 2003a, 2003b). For BPA, 13 gavage
studies at 600 mg/kg/day and 25 sc studies at
300 mg/kg/day in the intact, immature female
and 12 sc studies at the same dose in the OVX
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Figure 4. (A) Group mean absolute blotted uterine control weights (milligrams) plotted against the esti-
mated total dietary genistein equivalents intake for intact, immature female groups in phase 2. The results
of specific groups from laboratories 6, 14, 19, 20, and 21 that are discussed in the text have been high-
lighted in light blue and labeled. Laboratory 20 has two data points. Laboratory 14 encountered a high
number of animal mortalities with protocol A (Kanno et al. 2003a, 2003b). (B) Group mean absolute blotted
uterine control weights (milligrams) plotted against the estimated total dietary GN equivalents for adult
OVX groups in phase 2. The results of speciﬁc groups from laboratories 6 and 19 that are discussed in the
text have been highlighted in light blue and labeled.adult are available. For NP, 13 gavage studies
at 250 mg/kg/day and 26 sc studies at
80 mg/kg/day in the intact, immature female
and 12 sc studies in the OVX adult are avail-
able. In this comparison, the ratio of geomet-
ric mean uterine blotted weight values for
treated animals relative to the vehicle controls
have been plotted with lower and upper 95%
conﬁdence limits against the calculated TGE
intake. The expectation is that any effect from
dietary phytoestrogen levels would be evident
in a decrease in the relative ratio as the dietary
phytoestrogen intakes increase.
The BPA oral gavage data for the intact,
immature female are shown in Figure 5A. By
this route, BPA is an extremely weak estrogen,
with the uterine weight increasing only
35–40% at 600 mg/kg/day (Table 10 in
Kanno et al. 2003a). Visually, the data suggest
a slight decrease in responsiveness with the cal-
culated TGE intakes. This suggestion is driven
by the results of laboratory 8 with a highest
mean relative uterine weight increase of 1.91
and an intake of 26–27 mg TGE/kg/day. A
linear least-squares analysis yields a very modest
negative slope and r2 value of only 0.265
(Table 3).
The BPA sc data for the intact, immature
female are shown in Figure 5B. No clear
decrease in bioassay responsiveness is visually
evident. However, consistent with concerns
for increased uterine control weights at high
TGE intakes, laboratory 20 was not responsive
to BPA at TGE intakes of about 75 mg
TGE/g diet, and laboratory 14 with the lowest
TGE intake had the highest relative increase
and achieved statistical significance by the
widest margin. Laboratory 6 with high uterine
control weights showed a limited relative
increase, but did achieve statistical signiﬁcance
at this BPA dose. Several other laboratories
with equal or higher TGE diets appeared to be
more responsive than laboratory 6. The only
other laboratory not achieving statistical signif-
icance is clustered with eight other laboratories
that did achieve statistical signiﬁcance (Figure
5B, lower 95% conﬁdence level < 1 at 46 mg
TGE/kg/day). Again, a linear least-squares
analysis yields a very modest negative slope and
an r2 value of 0.296. When the data from labo-
ratory 20 are excluded, the slope is reduced by
half, and the r2 value falls to 0.053 (Table 3).
The BPA sc data for adult OVX are
shown in Figure 5C. All laboratories achieved
statistical significance, and the relative
increase in uterine weights actually rose
slightly with higher TGE intakes. Laboratory
6, with the highest control uterine weight,
and laboratory 19, with the lowest TGE
intakes, had somewhat lower responses when
compared with the results in other laborato-
ries. In this case, the least-squares analysis
gave a positive rather than negative slope, and
the r2 value was 0.196 (Table 3).
The NP po data for the intact, immature
female are shown in Figure 6A. No decrease in
responsiveness of the bioassay with increasing
TGE intakes is evident. Only laboratory 12
did not achieve statistical significance.
Although the mean relative increase in uterine
weight was similar to the other laboratories,
four animals died in this laboratory, leaving
only two survivors and seriously reducing the
power (Kanno et al. 2003a). Laboratory 14,
with the lowest estimated TGE intake, showed
no evident increase in responsiveness compared
with other laboratories. Least-squares analysis
showed a very modest negative slope and an r2
value of only 0.017 (Table 3).
The NP sc data for the intact, immature
female are shown in Figure 6B. Again, no
visual trend in decreased responsiveness of the
bioassay with the estimated TGE intakes is
evident. Seven studies did not achieve statisti-
cal signiﬁcance, but the TGE intakes for the
ﬁrst six ranged from 15 to 50 mg/g diet where
other laboratories successfully achieved statisti-
cal signiﬁcance. Laboratory 19, with the low-
est TGE intakes, also did not achieve
statistical signiﬁcance, and laboratory 14, with
the second lowest TGE intakes, was no more
responsive on average than other laboratories.
Laboratory 6, with the highest uterine control
weights, was one of the laboratories not
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Figure 5. (A) The ratio of the geometric mean blotted uterine weights adjusted for body weight of the groups treated by oral gavage with 600 BPA mg/kg/day rela-
tive to control vehicle uterine weights are plotted against the estimated total dietary genistein equivalents intake for intact, immature female groups in phase 2.
The 95% upper and lower conﬁdence levels are included. The results of speciﬁc groups from laboratories 8 and 14 that are discussed in the text has been high-
lighted in light blue and labeled. (B) The ratio of the geometric mean blotted uterine weights adjusted for body weight of the groups treated by sc injection with
300 BPA mg/kg/day relative to control vehicle uterine weights are plotted against the estimated total dietary genistein equivalents intake for intact, immature
female groups in phase 2. The 95% upper and lower conﬁdence levels are included. The results of speciﬁc groups from laboratories 6, 14, and 20 that are dis-
cussed in the text have been highlighted in light blue and labeled. (C) The ratio of the geometric mean blotted uterine weights adjusted for body weight of the
groups treated by sc injection with 300 BPA mg/kg/day relative to control vehicle uterine weights are plotted against the estimated total dietary genistein equiva-
lents intake for adult OVX groups in phase 2. The 95% upper and lower conﬁdence levels are included. The results of speciﬁc groups from laboratories 6 and 19
that are discussed in the text have been highlighted in light blue and labeled. 
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Table 3. Linear least-squares analyses of dietary total estimated GN intake (milligram per kilogram per day)
against the ratio of relative increase of the blotted uterine weights in the treated group and vehicle group.
Protocol A Protocol B Protocol C
Linear equation r2 Linear equation r2 Linear equation r2
BPA –0.0111x + 1.8462 0.265 –0.0161x + 2.4539 0.296 0.0299x + 2.2452 0.196
–0.0089x + 2.2007a 0.053
GN –0.0017x + 2.8993 0.002 –0.0274x + 3.5953 0.630 –0.0365x + 2.4806 0.444
–0.0231x + 3.4422a 0.393
Methoxychlor –0.0044x + 3.3632 0.018 –0.0309x + 4.3111 0.519 0.0067x + 2.0387 0.003
–0.0273x + 4.184a 0.325
NP –0.0049x + 2.4103 0.017 –0.002x + 1.6629 0.007 0.0058x + 1.2591 0.043
0.013x + 1.167a 0.154
o,p´-DDT –0.0258x + 4.5469 0.282 –0.0011x + 1.3166 0.003 0.0151x + 1.0125 0.179
0.0076x + 1.017a 0.079
aThe values for the high phytoestrogen diet in laboratory 20 were omitted and the least-squares analysis was performed
to assess the inﬂuence of these data on the overall trend.achieving statistical significance. However,
laboratory 20, with the highest estimated
TGE intake of 75 mg/kg/day, had no evident
response to this NP dose. The least-squares
analysis showed a modest negative slope and
an r2 value of only 0.007, and the omission of
laboratory 20 resulted in a slightly positive
slope and an r2 value of 0.154 (Table 3).
The data for the adult OVX animals
administered NP via sc injection are shown in
Figure 6C. No obvious decrease in responsive-
ness of the bioassay was evident with the
intakes all < 25 mg TGE/kg/day. The response
to this dose of NP, like the immature groups,
is lower than with the BPA dose. Four of the
studies did not achieve statistical signiﬁcance,
although the lower 95% confidence level
approached statistical signiﬁcance in all cases.
All four of these studies had intermediate levels
of dietary phytoestrogen intakes. One of these
groups was in laboratory 6, with the highest
control uterine weights. Laboratory 19, with
the lowest dietary TGE intake, was not more
responsive than other groups.
Laboratory 21 has not been included in
Figures 4A and 5A, as it failed to record body
weights at necropsy, and relative increase in
uterine weights adjusted for body weights could
not be calculated. As 54 mg TGE/kg/day in
this laboratory was the second highest intake, a
close examination of the uterine weights them-
selves for BPA and NP is warranted. In BPA
dose–response studies, an increase in absolute
uterine weights was present, dose related, and
achieved statistical significance (Kanno et al.
2003a, 2003b). However, the relative values
were not as high as other laboratories at the
maximum BPA doses (see Table 3B and
Figure 1 in Kanno et al. 2003b). In NP
dose–response studies, the uterine weights dis-
played a pattern of higher baseline values and
relative uterine weight increases were lower
than other laboratories (see Table 5B and
Figure 4 in Kanno et al. 2003b). Therefore,
these data are generally consistent with a pat-
tern of diminished bioassay responsiveness at
high estimated TGE intakes.
To further assess the possibility of a
dietary phytoestrogen impact, data for the
other weak estrogen agonists GN, methoxy-
chlor, and o,p´-DDT from protocols A, B,
and C were analyzed for a linear trend using
the least-squares method. The results are
shown in Table 3. The slopes are again mod-
estly negative for protocols A and B. The r2
values for protocol A range from 0.002 to
0.282. The r2 values for protocol B that
include laboratory 20 are somewhat higher
for GN and methoxychlor (0.630 and 0.519,
respectively). The slopes for protocol C are
slightly negative in the case of GN and posi-
tive for the other two weak agonists, and the
r2 values range from 0.444 to 0.003.
Discussion and Conclusions
These studies were performed to validate the
intact, immature female and adult OVX ver-
sions of the uterotrophic bioassays (Kanno et al.
2001, 2003a, 2003b; OECD 1998a). Although
not a controlled experiment, the size of the data
set presents an excellent opportunity to test for
possible inﬂuence of dietary phytoestrogens and
other factors on the responsiveness of the bioas-
say. Because of the different nomenclatures
between statistical sensitivity and its use in vali-
dation, namely, the proportion of all positive
chemicals that are correctly classiﬁed as positive
in an assay (ICCVAM 1997; OECD 1998b),
the term responsiveness is used to describe the
ability of an assay to respond to a substance at
somewhat lower doses or even to achieve a
statistically signiﬁcance difference at any dose.
The data taken as a whole support the
ability of laboratories using these uterotrophic
protocols to detect weak estrogen agonists
in vivo even when diets contain significant
levels of phytoestrogens. This appears to
resolve the concerns that dietary phytoestro-
gen levels per se may deleteriously impact the
performance of the bioassay (Brown and
Setchell 2001; Thigpen et al. 1999b). No evi-
dence was found in the adult OVX version
that estimated intakes < 25 mg TGE/kg/day
would increase control blotted uterine weights
or decrease the responsiveness of the bioassay
(Figures 4B, 5C, 6C; Table 3). For the intact
immature animals, the data do suggest a grad-
ual increase in control uterine weights as
phytoestrogen intakes rise, and two laborato-
ries with intakes > 50 mg TGE/kg/day dis-
played an apparent decrease in responsiveness.
Laboratory 20, with the highest TGE intakes,
did not respond to either test substance when
numerous other laboratories achieved statisti-
cally signiﬁcant uterine weight increases, and
the data from laboratory 21, with the second
highest doses, provide tentative support
(Figures 4A, 5A,B, 6A,B; Table 3). However,
some caution is necessary before arriving at
any conclusions. In the NP dose–response
studies, the mean of the control uterine weight
in laboratory 20 was 54 mg, and the means of
the test substances were 34–41 mg. This sug-
gests that the control value could be an anom-
aly and not due to dietary phytoestrogens. The
BPA dose–response studies used the same con-
trol, and the test substance uterine weight
means ranged from 27 to 97 mg, further
suggesting the control could be an anomaly.
The higher food consumption rates of the
immature animals relative to their body
weights appears central to this possible differ-
ence between the intact, immature and adult
OVX versions. Higher food consumption rates
effectively double the phytoestrogen intake of
the immature animals when compared with
Mini-Monograph | Owens et al.
1564 VOLUME 111 | NUMBER 12 | September 2003 • Environmental Health Perspectives
Figure 6. (A) The ratio of the geometric mean blotted uterine weights adjusted for body weights of the groups treated by oral gavage with 250 NP mg/kg/day rela-
tive to control vehicle uterine weights are plotted against the estimated total dietary genistein equivalents intake for intact, immature female groups in phase 2.
The 95% upper and lower conﬁdence levels are included. The results of speciﬁc groups from laboratory 14 that are discussed in the text have been highlighted in
light blue and labeled. (B) The ratio of the geometric mean blotted uterine weights adjusted for body weight of the groups treated by sc injection with 80 NP
mg/kg/day relative to control vehicle uterine weights are plotted against the estimated total dietary genistein equivalents intake for intact, immature female
groups in phase 2. The 95% upper and lower conﬁdence levels are included. The results of speciﬁc groups from laboratories 6, 14, 19, and 20 that are discussed in
the text have been highlighted in light blue and labeled. (C) The ratio of the geometric mean blotted uterine weights adjusted for body weights of the groups
treated by sc injection with 80 NP mg/kg/day relative to control vehicle uterine weights are plotted against the estimated total dietary genistein equivalents intake
for adult OVX groups in phase 2. The 95% upper and lower conﬁdence levels are included. The results of speciﬁc groups from laboratories 6 and 19 that are dis-
cussed in the text have been highlighted in light blue and labeled.
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Cthe adult OVX animals on the same diet. The
same higher food consumption is also note-
worthy for the mouse, an alternative species for
the uterotrophic bioassay, as mouse intakes
from an equivalent diet would be even higher
than that of the immature rat.
Much of this examination and its
conclusions hinge on chemical analyses of the
diets and estimation of TGE intakes. The ana-
lytical method has been published previously
and used (Morton et al. 1994; Odum et al.
2001). These data are based upon mass spectra
ion fragments. Those samples that are effec-
tively lot duplicates are in close agreement;
and the levels and ratios of GN, DN, and CM
are in close agreement with HPLC analyses
with ultraviolet detection of various North
American and European diets (Brown and
Setchell 2001; Degen et al. 2002; Thigpen
et al. 1999a, 1999b). This same method has
been studied in a small interlaboratory study
with a standardized soya flour sample
(Wiseman et al. 2002). The expected result
was returned with this method, indicating that
enzymatic hydrolysis and recovery were ade-
quate (Clarke D. Personal communication).
Similar results for the analysis of rodent diet
PMI 5002 (Purina Mills, St. Louis, MO),
allowing for possible batch variations between
diets, were obtained with this method [DN 88
µg/g, GN 204 µg/g for laboratory 5, and DN
117 µg/g, GN 218 µg/g diet for laboratory 12
(Table 2)] and by Thigpen et al. (1999b) (DN
86 µg/g, GN 73 µg/g diet), again indicating
that this method is comparable with those of
others. In contrast, the estimation of TGE
rests on a) the largely untested assumption of
direct additivity between weak ER agonists in
vivo, and b) an assessment of various literature
data to derive the potency of various phytoe-
strogens. The tissue speciﬁcity of ER ligands
(Shang and Brown 2002) and the interaction
studies of Edgren and Calhoun (1957, 1960,
1961) suggest both caution and the need for
robust experimental data.
Based on the uterotrophic data, the
analytical data, and the TGE assumptions and
calculations, this analysis suggests that TGE
intakes > 40–50 mg/kg/day should be in ques-
tion and avoided. This in turn suggests a limit
of 325–350 µg TGE/g diet for immature ani-
mals. This judgment is consistent with the
biological activity of pure phytoestrogens in
other uterotrophic studies and other toxico-
logic studies. This intake limit is near the GN
uterotrophic lowest observable effect level
(LOEL) from this same validation program
(Kanno et al. 2003b). In toxicologic studies
employing soy-free diets, biological responses
consistent with an estrogenic mode of action
have been observed at GN LOELs between
300 and 1,000 µg/g diet (Casanova et al.
1999; Delclos et al. 2001; Fritz et al. 1998;
Santell et al. 1997; You et al. 2002a, 2002b).
Two controlled dietary studies have been
recently performed specifically to test the
impact of dietary phytoestrogens on the
uterotrophic bioassay, and these data are consis-
tent with our conclusion that low levels of
dietary phytoestrogens do not significantly
impair the uterotrophic bioassay. Yamasaki
et al. (2002) fed rats diets containing approxi-
mately 20, 100, and 200 µg TGE/g diet as cal-
culated herein with dose ranges of BPA, GN,
and NP. No effect on the responsiveness of the
uterotrophic bioassay was observed, and the
phytoestrogen intakes at the high dose would
have been approximately 30 mg TGE/kg/day
diet. In a second study, rats were fed a series of
diets containing 5, 50, 250, and 1,250 µg
Novasoy extract/g diet and compared the
responsiveness of the uterotrophic assay and
several other uterine indicators to administered
doses of EE (1 µg/kg/day) and BPA (600
mg/kg/day). These doses are sufﬁcient to attain
near-maximal responses by sc injection (Kanno
et al. 2003b). A statistically signiﬁcant increase
in uterine weights with 1,250 µg Novasoy
extract/g diet was observed. However, no inter-
action was evident with either the EE or BPA
with the blotted uterine weight or the measured
increase in the uterine epithelial cell height at
any dietary level of the Novasoy extract (Wade
MG, Lee A, McMahon A, Cooke G, Curran I.
Personal communication). Both of these data
sets are comparable to ours, as the same
protocol B was used in those studies.
The implications for these observations
extend to other areas of current interest.
Experimental data have raised the question of
whether very low doses of BPA, for example,
2 or 20 µg/kg/day orally administered, might
result in observable changes in several end
points in the mouse (Howdeshell et al. 2000;
Nagel et al. 1997; vom Saal et al. 1998).
These investigators reported using PMI 5001
and 5008 diets, which are reported elsewhere
to contain levels of phytoestrogens that would
approach or exceed 300–350 µg TGE/g diet
(Brown and Setchell 2001; Degen et al. 2002;
Odum et al. 2001; Thigpen et al. 1999b). As
previously noted, mice consume even higher
quantities of diet than rats on a relative body
weight basis. For example, in National
Toxicology Program studies, mice consumed a
mean of 7.2 g diet/day for a 25 g bw, or
288 g/kg bw/day, and rats consumed a mean
of 14.8 g diet/day for a 200 g bw, or 74 g/kg
bw/day (Moore 1995). The latter quantity
compares favorably with the data and
calculations herein of 60–75 g/kg bw/day,
considering that OVX animals here were
somewhat higher in body weight and their
food intake should have then slightly
decreased. Using dietary phytoestrogen levels
of 200 and 350 µg TGE/g diet, we then esti-
mate the TGE intake from the laboratory diet
like those low-dose BPA studies to have been
in the approximate range of 50–100 mg
TGE/kg/day.
Four presumptions are needed to estimate
the dose of BPA relative to dietary TGE
intakes in these studies: a) an equivalency fac-
tor for BPA of 0.06 based upon directly com-
parable data from po administration of BPA
and GN in this validation program (Kanno
et al. 2003a, 2003b); b) the additive interac-
tion of phytoestrogens and BPA as estrogens;
c) a molecular similarity of action via the ER
in both rat uterus and mouse tissues; and d)
similar pharmacokinetics in both species, such
as similar levels of hepatic glucuronidation
and rates of biliary excretion. These presump-
tions lead to an estimate that the BPA doses
would then have contributed only approxi-
mately 0.12 and 1.2 µg TGE/kg/day, or
about 0.002% of the estimated dietary TGE
dose ingested by these animals. This may
assist in explaining the inability of other
workers to reproduce the original data (Ashby
et al. 1999a; Cagen et al. 1999).
Human exposures to phytoestrogens are
variously estimated to range from 0.5 to
4 mg/kg/day for adults and 4.5 to 10 mg/kg/
day for infants consuming soy-based infant for-
mula (MAFF UK 1998; Setchell et al. 1997;
Whitten and Patisaul 2001). This level of
dietary intake would then be the predominate
human exposure to exogenous estrogens other
than pharmaceuticals. In addition to the appar-
ent LOEL of approximately 50 mg/kg/day
based on this dietary analysis, these intakes are
within range of the GN po LOEL in this vali-
dation program (Kanno et al. 2003b) and the
range of LOELs/lowest observable adverse
effect levels observed in several toxicologic stud-
ies (Casanova et al. 1999; Delclos et al. 2001;
Fritz et al. 1998; Newbold et al. 2001; Santell
et al. 1997; Whitten et al. 1992; Whitten and
Naftolin 1992; You et al. 2002a, 2002b). This
indicates that human phytoestrogen consump-
tion warrants examination as a model for any
risk presented by estrogenic substances.
Other tasks at hand are to identify condi-
tions that may impair the performance of the
bioassay or prevent acceptance of data from
the bioassay and to recommend remedies. The
validation data indicate several instances where
the responsiveness of the uterotrophic bioassay
may have been diminished, particularly, by
high control uterine weights, that are not
attributable to dietary phytoestrogen levels.
For example, laboratory 6 had phytoestrogen
levels similar to a number of other laborato-
ries, and laboratory 19 had both low dietary
TGE values and normal control uterine
weights, yet decreased responsiveness in these
laboratories was evident for several test sub-
stances (Kanno et al. 2003a, 2003b). To fur-
ther reinforce the evidence against a role for
phytoestrogens, note that laboratory 14 used
the same diet as laboratory 6, laboratory 8
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and neither laboratories 14 and 8 experienced
any evident problems.
There is evidence that dietary factors
other than phytoestrogens levels may affect
uterine weights and the timing of vaginal
opening (Ashby et al. 1999b, 2000, 2001;
Odum et al. 2001; Thigpen et al. 1987a,
1987b). In fact, some purified diets, free of
phytoestrogens, have yielded statistically sig-
nificant increases in uterine weights when
compared with diets with limited quantities
of phytoestrogens (Ashby et al. 1999b, 2001).
Upon investigation, increasing levels of
endogenous, prepubertal estrogens are plausi-
ble factors, as co-administration of the estro-
gen receptor antagonist Faslodex (Ashby
1999b) or the gonadotrophin-releasing hor-
mone antagonist Antarelix (Odum et al.
2001) reduce the increased uterine sizes from
these diets to even lower levels.
We suggest that several precautions will
beneﬁt the development of guidelines for the
uterotrophic bioassay. First, laboratories
should request that diets have total GN and
DN levels < 350 µg/g diet where immature
animals are used. Occasional analyses may be
needed to verify the levels. Second, laborato-
ries should monitor the uterine weights of
their laboratory colonies or those of the ani-
mals from their supplier. We suggest that blot-
ted uterine weights for control immature
animals should be consistently < 35 mg, and
mean blotted uterine weights > 40 mg should
be questioned. In the case of adult OVX ani-
mals, in addition to monitoring the animals at
necropsy for complete ovariectomy, mean
blotted uterine weights > 115 mg should be
questioned. Third, the OECD validation
studies provide a base data set to compare the
performance of established laboratories and to
qualify new laboratories. This data set includes
the potent reference EE, and the large BPA or
NP data sets apply to the likely target area of
weak ER agonists. In addition, these data
should also assist the design of more deﬁnitive
and controlled experiments on the possible
effect of laboratory diets.
We conclude that modest to low levels of
dietary phytoestrogens do not substantially
increase control uterine weights or reduce the
responsiveness of the uterotrophic bioassay to
weak ER agonists. Therefore, laboratories con-
ducting the uterotrophic bioassay for regula-
tory or research purposes can continue to use
diets containing levels of phytoestrogens
< 325–350 µg TGE/g diet. Above these levels,
the evidence suggests that phytoestrogens may
compromise the responsiveness in the case of
the intact immature version of the bioassay.
As food intake relative to body weight is an
essential factor in determining actual intake,
these cautions should also be applied to the
mouse when used in the uterotrophic bioassay.
Laboratories should also be aware of data sug-
gesting that even phytoestrogen-free diets may
impair the responsiveness of the bioassay under
some conditions.
There were other instances of high baseline
uterine weights and limited responsiveness that
cannot be attributed to the phytoestrogen con-
tent of the diets. Therefore, we also conclude
for purposes of quality control that laboratories
conducting the uterotrophic bioassay for either
research or regulatory purposes should monitor
the uterine weights of their control groups for
data acceptance. Laboratories should also peri-
odically demonstrate the adequate responsive-
ness of their systems to estrogen agonists. In
this respect, the OECD data set for EE and
ﬁve weak agonists can be used for performance
comparisons and to benchmark laboratory
performance over time.
REFERENCES
Ashby J, Tinwell H, Haseman J. 1999a. Lack of effects for low
dose levels of bisphenol A and diethylstilbestrol on the
prostate gland of CH nice exposed in utero. Regul Toxicol
Pharmacol 30:156–166.
Ashby J, Tinwell H, Odum J. 1999b. Uterotrophic activity of a
“phytoestrogen-free” diet. Environ Health Perspect
108:A12–A13.
———. 2001. DNA adducts, estrogenicity and rodent diets.
Mutat Res 483:105–106.
Ashby J, Tinwell H, Odum J, Kimber I, Brooks AN, Pate I, et al.
2000. Diet and the aetiology of temporal advances in
human and rodent sexual development. J Appl Toxicol
20:343–347.
Bickoff EM, Livingston AL, Hendrickson AP, Booth AN. 1962.
Relative potencies of several estrogen-like compounds
found in forages. Agric Food Chem 10:410–412.
Boettger-Tong H, Murphy L, Chiappetta C, Kirkland JL,
Goodwin B, Aldercreutz H, et al. 1998. A case of a labora-
tory animal feed with high estrogenic activity and its
impact on in vivo responses to exogenously administered
estrogens. Environ Health Perspect 106:369–373.
Branham WS, Dial SL, Moland CL, Hass BS, Blair RM, Fang H,
et al. 2002. Phytoestrogens and mycoestrogens bind to the
rat uterine estrogen receptor. J Nutr 132:658–664.
Brown NM, Setchell KDR. 2001. Animal models impacted by
phytoestrogens in commercial chow: implications for
pathways inﬂuenced by hormones. Lab Invest 81:735–747.
Cagen SZ, Waechter JM Jr, Dimond SS, Breslin WJ, Butala JH,
Jekat FW, et al. 1999. Normal reproductive organ develop-
ment in CF-1 mice following prenatal exposure to bisphe-
nol A. Toxicol Sci 50:36–44.
Casanova M, You L, Gaido KW, Archibeque-Engle S, Jansen
DB, Heck HA. 1999. Developmental effects of dietary phy-
toestrogens in Sprague-Dawley rats and interactions of
genistein and daidzein with rat estrogen receptors α and
β in vitro. Toxicol Sci 51:236–244.
Degen GH, Janning P, Diel P, Bolt HM. 2002. Estrogenic
isoﬂavones in rodent diets. Toxicol Lett 128:145–157.
Delclos KB, Bucci TJ, Lomax LG, Latendresse JR, Warbritton A,
Weiss CC, et al. 2001. Effects of dietary genistein exposure
during development on male and female CD (Sprague-
Dawley) rats. Reprod Toxicol 15:647–663.
Drane HM, Patterson DSP, Roberts BA , Saba N. 1975. The
chance discovery of oestrogenic activity in laboratory rat
cake. Food Cosmet Toxicol 13:425–427 (1975).
———. 1980. Oestrogenic activity of soya-bean products.
Food Cosmet Toxicol 18:491–492 (1980).
Edgren RA, Calhoun DW. 1957. Estrogen antagonisms: inhibi-
tion of estrone-induced uterine growth by testosterone
propionate, progesterone and 17-ethyl-19-nortestos-
terone. Proc Soc Exp Biol Med 94:537–539.
———. 1960. Oestrogen antagonisms: the effects of oestriol
and 16-epi-oestriol on oestrone-induced uterine growth in
spayed rats. J Endocrinol 20:325–330.
———. 1961. Oestrogen antagonisms: the effects of various
steroids on oestrone-induced uterine growth in spayed
rats. Endocrinology 68:633–638.
Farmakalidis E, Hathcock JN, Murphy PA. 1985. Oestrogenic
potency of genistin and daidzin in mice. Food Chem
Toxicol 23:741–745.
Farmakalidis E, Murphy PA. 1984. Oestrogenic response of the
CD-1 mouse to the soya-bean isoflavones genistein,
genistin and daidzin. Food Chem Toxicol 22:237–239.
Fritz WA, Coward L, Wang J, Lamartiniere CA. 1998. Dietary
genistein: perinatal mammary cancer prevention, bioavail-
ability and toxicity testing in the rat. Carcinogenesis
19:2151–2158.
Howdeshell KL, Hotchkiss AK, Thayer KA, Vandenbergh JG,
vom Saal FS. Exposure to bisphenol A advances puberty.
Nature 2000; 401:763–764.
Huggins C, Jensen EV, Cleveland AS. 1954. Chemical structure
of steroids in relation to promotion of growth of the vagina
and uterus of the hypophysectomized rat. J Exp Med
100:225–243.
ICCVAM (Intraagency Coordinating Committee on the
Validation of Alternative Methods). 1997. Validation and
Regulatory Acceptance of Toxicological Test 5ethods. A
5eport of the Ad Hoc Interagency Coordinating Committee
on the Validation of Alternative Methods. NIH Report No.
97-3981. Research Triangle Park, NC:National Institute of
Environmental Health Sciences. 
Jefferson WN, Newbold RR. 2000. Potential endocrine-modu-
lating effects of various phytoestrogens in the diet.
Nutrition 16:658–662.
Kanno J, Onyon L, Haseman J, Fenner-Crisp P, Ashby J, Owens
W. 2001. The OECD program to validate the rat uterotrophic
bioassay to screen compounds for in vivo estrogenic
responses: phase 1. Environ Health Perspect 109:785–794.
———. 2003a. The OECD program to validate the rat
uterotrophic bioassay. Phase 2: coded single-dose stud-
ies. Environ Health Perspect 111:1550–1558.
Kanno J, Onyon L, Peddada S, Ashby J, Jacob E, Owens W.
2003b. The OECD program to validate the rat uterotrophic
bioassay. Phase 2: dose-response studies. Environ Health
Perspect 111:1530–1549.
———. 2003b. The OECD program to validate the rat
uterotrophic bioassay. Phase 2: coded single dose studies.
Environ Health Perspect 111:1550–1558.
Kuiper GG, Carlsson B, Grandien K, Enmark E, Häggblad J,
Nilsson S, et al. 1997. Comparison of the ligand binding
specificity and transcript tissue distribution of estrogen
receptors α and β. Endocrinology 138:863–870.
Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson J-
Å. 1996. Cloning of a novel estrogen receptor expressed in
rat prostate and ovary. Proc Natl Acad Sci USA
93:5925–5930.
Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van
der Saag PT, et al. 1998. Interaction of estrogenic chemi-
cals and phytoestrogens with estrogen receptor β.
Endocrinology 139:4252–4263.
MAFF UK (Ministry of Agriculture, Fisheries and Food of the
United Kingdom). 1998. Plant oestrogens in soya-based
infant formulae. MAFF Food Surveillance Information
Sheet 167:1–8.
Markaverich BM, Webb B, Densmore CL, Gregory RR. 1995.
Effects of coumestrol on estrogen receptor function and
uterine growth in ovariectomized rats. Environ Health
Perspect 103:574–581.
McKenna NJ, Lanz RB, O’Malley BW. 1999. Nuclear receptor
coregulators: cellular and molecular biology. Endocr Rev
20:321–344.
Moore JA. Institute for Evaluating Health Risks Expert
Scientiﬁc Committee. 1995. An assessment of lithium using
the IEHR evaluative process for assessing human devel-
opmental and reproductive toxicity of agents. Reprod
Toxicol 9:175–210.
Moras D, Gronemeyer H. 1998. The nuclear receptor ligand-
binding domain: structure and function. Curr Opin Cell Biol
10:384–391.
Morton MS, Wilcox G, Wahlqvist ML, Griffiths K. 1994.
Determination of lignins and isoﬂavonoids in human female
plasma following dietary supplementation. J Endocrinol
142: 251–259.
Nagel SC, vom Saal FS, Thayer KA, Dhar MG, Boechler M,
Welshons WV. 1997. Relative binding afﬁnity-serum modi-
ﬁed access (RBA-SMA) assay predicts the relative in vivo
bioactivity of the xenoestrogens bisphenol A and
octylphenol. Environ Health Perspect 105:70–76.
Mini-Monograph | Owens et al.
1566 VOLUME 111 | NUMBER 12 | September 2003 • Environmental Health PerspectivesNewbold RR, Banks ED, Bullock B, Jefferson WN. 2001. Uterine
adenocarcinoma in mice treated neonatally with genis-
tein. Cancer Res 61:4325–4328.
Odum J, Lefevre PA, Tittensor S, Paton D, Routledge EJ,
Beresford NA, et al. 1997. The rodent uterotrophic bioas-
say: critical protocol features, studies with nonylphenols,
and comparison with a yeast estrogenicity assay. Regul
Toxicol Pharmacol 25:176–188.
Odum J, Tinwell H, Jones K, Van Miller JP, Joiner RL, Tobin G,
et al. 2001. Effect of rodent diets on the sexual develop-
ment of the rat. Toxicol Sci 61:115–127.
OECD (Organisation for Economic Co-operation and
Development). 1998a. Report of the First Meeting of the
OECD Endocrine Disrupter Testing and Assessment (EDTA)
Working Group, 10–11 March 1998. ENV/MC/CHEM/RA(98)5.
Paris:OECD.
———. 1998b. The Validation of Test Methods Considered for
Adoption as OECD Test Guidelines. ENV/MC/CHEM(98)6.
Paris:OECD.
———. 2000. Guidance Document on the Recognition,
Assessment, and Use of Clinical Signs as Humane Endpoints
for Experimental Animals Used in Safety Evaluation. OECD
Environmental Health and Safety Publications. Series on
Testing and Assessment, No. 19. ENV/JM/MOMO(2000)7.
Paris:OECD.
Perel E, Linder HR. 1970. Dissociation of uterotrophic action
from implantation-inducing activity in two non-steroidal
oestrogens (coumestrol and genistein). J Reprod Fertil
21:171–175.
Safe SH, Pallaroni L, Yoon K, Gaido K, Ross S, Saville B, et al.
2001. Toxicology of environmental estrogens. Reprod Fertil
Dev 13:307–315.
Santell RC, Chang YC, Nair MG, Helferich WG. 1997. Dietary
genistein exerts estrogenic effects upon the uterus,
mammary gland and the hypothalamic/pituitary axis in
rats. J Nutr 127:263–269.
Setchell KDR, Welsh MB, Lim CK. 1987. High performance liq-
uid chromatographic analysis of phytoestrogens in soy
protein preparations with ultraviolet, electrochemical and
thermospray mass spectrometric detection. J Chromatogr
386: 315–323.
Setchell KDR, Zimmer-Nechemias L, Cai J, Heubi JE. 1997.
Exposure of infants to phyto-oestrogens from soy-based
infant formula. Lancet 350:23–27.
Shang Y, Brown M. 2002. Molecular determinants for the tissue
speciﬁcity of SERMs. Science 295:2465–2468.
Thigpen JE, Li L-A, Richter CB, Lebetkin EH, Jameson CW.
1987a. The mouse bioassay for the detection of estrogenic
activity in rodent diets. II. Comparative estrogenic activity
of purified, certified and standard open and closed for-
mula rodent diets. Lab Anim Sci 37:602–605.
Thigpen JE, Lebetkin EH, Dawes ML, Richter CB, Crawford D.
1987b. The mouse bioassay for the detection of estrogenic
activity in rodent diets. III. Stimulation of uterine weight by
dextrose, sucrose and corn starch. Lab Anim Sci
37:606–609.
Thigpen JE, Setchell KD, Goelz MF, Forsythe DB. 1999a. The
phytoestrogen content of rodent diets [Letter]. Environ
Health Perspect 107:A182–A183.
Thigpen JE, Setchell KD, Ahlmark KB, Locklear J, Spahr T,
Caviness GF, et al. 1999b. Phytoestrogen content of puri-
ﬁed, open and closed-formula laboratory animal diets. Lab
Anim Sci 49:530–536.
vom Saal FS, Cooke PS, Buchanan DL, Palanza P, Thayer KA,
Nagel SC, et al. 1998. A physiologically based approach to
the study of bisphenol A and other estrogenic chemicals
on the size of reproductive organs, daily sperm production
and behavior. Toxicol Ind Health 14:239–260.
Wiseman H, Casey K, Clarke DB, Barnes KA, Bowey E. 2002.
Isoflavone aglycon and glucoconjugate content of high-
and low-soy U.K. foods used in nutritional studies. J Agric
Food Chem 50:1404–1410.
Whitten PL, Naftolin F. 1992. Effects of a phytoestrogen diet on
estrogen-dependent reproductive processes in immature
female rats. Steroids 57:56–61.
Whitten PL, Patisaul HB. 2001. Cross-species and interassay
comparisons of phytoestrogen action. Environ Health
Perspect 109(suppl 1):5–20.
Whitten PL, Russell E, Naftolin F. 1992. Effects of a normal,
human-concentration, phytoestrogen diet on rat uterine
growth. Steroids 57:98–106.
Xu L, Glass CK, Rosenfeld MG. 1999. Coactivator and corepres-
sor complexes in nuclear receptor function. Curr Opin Gen
Dev 9:140–147.
Yamasaki K, Sawaki M, Noda S, Wada T, Hara T, Takatsuki M.
2002. Immature uterotrophic assay of estrogenic com-
pounds in rats given different phytoestrogen content diets
and the ovarian changes in the immature rat uterotrophic
of estrogenic compounds with ICI 182,780 or antide. Arch
Toxicol 76: 613–620.
You L, Casanova M, Bartolucci EJ, Fyczynski MW, Dorman DC,
et al. 2002a. Combined effects of dietary phytoestrogen
and synthetic endocrine-active compound on reproduc-
tive development in Sprague-Dawley rats: genistein and
methoxychlor. Toxicol Sci 66:91–104.
You L, Sar M, Bartolucci EJ, McIntyre BS, Sriperumbudur R.
2002b. Modulation of mammary gland development in pre-
pubertal male rats exposed to genistein and methoxychlor.
Toxicol Sci 66:216–225.
Zarrow MX, Lazo-Wasem EA, Shoger RL. 1953. Estrogenic
activity in a commercial animal ration. Science
118:650–651.
Mini-Monograph | Uterotrophic bioassay validation—dietary analyses
Environmental Health Perspectives • VOLUME 111 | NUMBER 12 | September 2003 1567